NRAS and autoimmune lymphoproliferative syndrome: Although most of the ALPS patients exhibit CD95 mutations, when Oliveira et al. revised the ALPS classification in 2010, lymphoproliferative disorders showing no mutations in CD95, CD95L, or caspase 10 were also classified as ALPS disorders (i.e., caspase 8, NRAS/KRAS, or SH2D1a mutations).